Sun Pharma receives FDA approval for generic Tiazac ANDA

Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE:SUNPHARMA, BSE: 524715) announced that USFDA has granted its subsidiary an approval for its Abbreviated New Drug Application (ANDA) to market a generic version of once-a-day Tiazac® extended release capsules.

These generic Tiazac capsules contain Diltiazem Hydrochloride Extended-release USP, 120 mg, 180 mg, 240 mg,300 mg and 360 mg, and are therapeutically equivalent to Biovail Corporation's Tiazac ® extended release capsules.

Generic Tiazac® Capsules are indicated for the treatment of hypertension, used alone or in combination with other antihypertensive medications. Generic Tiazac® Capsules are also used in the treatment of Chronic stable angina.

Extended release Diltaizem Hydrochloride USP capsules have annual sales of approximately $ 46 million in the US.

Source:

 Sun Pharmaceutical Industries Ltd.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Antibiotic resistance threatens millions of lives worldwide